NCT02837991 2020-06-04
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
Celldex Therapeutics
Celldex Therapeutics
Celldex Therapeutics